JPMorgan initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 1,100 price target The firm cites the company’s obesity pipeline strength, in particular long acting Amylin, with likely partnering validation in 2025, for the bullish rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma’s 2024 Progress and Financial Results
- Zealand Pharma issued Complete Response Letter for dasiglucagon in CHI
- Zealand Pharma reports Breakthrough Therapy designation for survodutide
- Zealand Pharma initiated with a Hold at Deutsche Bank
- Zealand Pharma announces topline results from Phase 1b trial of dapiglutide